99 related articles for article (PubMed ID: 3132514)
1. Differential efficacies of recombinant murine interferon-gamma and recombinant human interleukin 2 against EL4-bearing mice.
Maekawa R; Kitagawa T; Hojo K; Sato K
J Interferon Res; 1988 Apr; 8(2):241-9. PubMed ID: 3132514
[TBL] [Abstract][Full Text] [Related]
2. Distinct antitumor mechanisms of recombinant murine interferon-gamma against two murine tumor models.
Maekawa R; Kitagawa T; Hojo K; Wada T; Sato K
J Interferon Res; 1988 Apr; 8(2):227-39. PubMed ID: 3132513
[TBL] [Abstract][Full Text] [Related]
3. [Enhancement of host defence against infection with Listeria monocytogenes in newborn mice by various recombinant cytokines].
Chen Y
Hokkaido Igaku Zasshi; 1991 Jan; 66(1):41-8. PubMed ID: 1900802
[TBL] [Abstract][Full Text] [Related]
4. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral rIL2-based immunotherapy in B16 melanoma.
Yeung RS; Vollmer C; Taylor DD; Palazzo J; Weese JL
J Surg Res; 1992 Aug; 53(2):203-10. PubMed ID: 1405610
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the co-promoting activity of gamma interferon in SENCAR and C57BL/6 mouse skin by difluoromethylornithine and the scheduling and duration of interferon treatment.
Reiners JJ; Pavone A; Rupp T; Cantu AR
Carcinogenesis; 1990 Jan; 11(1):129-37. PubMed ID: 2104781
[TBL] [Abstract][Full Text] [Related]
7. Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.
Mitsunaga S; Kimura H; Yamaguchi Y; Mikata A
Jpn J Cancer Res; 1988 Aug; 79(8):965-72. PubMed ID: 3141331
[TBL] [Abstract][Full Text] [Related]
8. Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model.
Moyes RB; Kirch H; DeLoach JR
Biotechnol Appl Biochem; 1996 Feb; 23(1):29-36. PubMed ID: 8867894
[TBL] [Abstract][Full Text] [Related]
9. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
10. Optimal circadian timing reduces the myelosuppressive activity of recombinant murine interferon-gamma administered to mice.
Koren S; Fleischmann WR
J Interferon Res; 1993 Jun; 13(3):187-95. PubMed ID: 8366285
[TBL] [Abstract][Full Text] [Related]
11. Augmentation by bacterial lipopolysaccharide of antitumor potency of murine recombinant interferon-gamma against Lewis lung adenocarcinoma.
Nagao S; Sato K; Ogawa H; Osada Y
Jpn J Cancer Res; 1986 Feb; 77(2):212-8. PubMed ID: 3082834
[TBL] [Abstract][Full Text] [Related]
12. Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity.
Visseren MJ; Koot M; van der Voort EI; Gravestein LA; Schoenmakers HJ; Kast WM; Zijlstra M; Melief CJ
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):119-28. PubMed ID: 8136944
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
Gautam SC; Chikkala NF; Ganapathi R; Hamilton TA
Cancer Res; 1991 Nov; 51(22):6133-7. PubMed ID: 1682042
[TBL] [Abstract][Full Text] [Related]
14. Murine interferon-gamma enhances resistance to infection with strains of Pseudomonas aeruginosa in mice.
Pierangeli SS; Polk HC; Parmely MJ; Sonnenfeld G
Cytokine; 1993 May; 5(3):230-4. PubMed ID: 8218935
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location.
Brunda MJ; Sulich V; Bellantoni D
Int J Cancer; 1987 Dec; 40(6):807-10. PubMed ID: 3121522
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cameron RB; McIntosh JK; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
[TBL] [Abstract][Full Text] [Related]
17. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
19. Circadian dependence of interferon antitumor activity in mice.
Koren S; Whorton EB; Fleischmann WR
J Natl Cancer Inst; 1993 Dec; 85(23):1927-32. PubMed ID: 8230283
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection.
Minagawa H; Takenaka A; Mohri S; Mori R
Antiviral Res; 1987 Sep; 8(2):85-95. PubMed ID: 2830846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
